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Background: Babies born very preterm (before 30 weeks gestation) are at high risk of dying in their first weeks of life,
and those who survive are at risk of developing cerebral palsy in childhood. Recent high-quality evidence has shown that
giving women magnesium sulphate immediately prior to very early birth can significantly increase the chances of their
babies surviving free of cerebral palsy. In 2010 Australian and New Zealand clinical practice guidelines recommended this
therapy. The WISH (Working to Improve Survival and Health for babies born very preterm) Project aims to bi-nationally
improve and monitor the use of this therapy to reduce the risk of very preterm babies dying or having cerebral palsy.
Methods/Design: The WISH Project is a prospective cohort study. The 25 Australian and New Zealand tertiary level
maternity hospitals will be provided with a package of active implementation strategies to guide the introduction and
local adaptation of guideline recommendations. Surveys will be conducted at individual hospitals to evaluate outcomes
related to local implementation progress and the use and value of the WISH implementation strategies. For the hospitals
participating in the ‘WISH audit of uptake and health outcomes data collection’, the primary health outcomes (assessed
through case note review, and 24 month corrected age questionnaires) will be: the proportion of eligible women
receiving antenatal magnesium sulphate; and rates of death prior to primary hospital discharge and cerebral palsy at
two years corrected age in infants born to eligible mothers. For hospitals wishing to assess factors influencing translation
locally, barriers and facilitators will be measured through interviews with health care professionals, to further guide
implementation strategies. Study outcomes for the early phase of the project (Year 1) will be compared with the later
intervention phase (Years 2 and 3).
Discussion: The WISH Project will offer insight into the effectiveness of a multifaceted implementation strategy to
improve the uptake of a novel neuroprotective therapy in obstetric clinical practice. The successful implementation of
antenatal magnesium sulphate for fetal neuroprotection in Australia and New Zealand could lead to over 90 fewer very
preterm babies dying or suffering the long-term consequences of cerebral palsy each year.
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Table 1 Summary of clinical recommendations from the
NHMRC endorsed Australian and New Zealand clinical
practice guidelines [10]
Clinical recommendations Grade^ Chapter
In women at risk of early preterm imminent
birth, use magnesium sulphate for
neuroprotection of the fetus, infant and child:
A 4-7
• When gestational age is less than 30 weeks. B 8
• When early preterm birth is planned or definitely
expected within 24 hours (when birth is planned,
commence magnesium sulphate as close to four
hours before birth as possible).
A 9
• Intravenously with a 4 gram loading dose
(slowly over 20–30 minutes) and 1 gram per hour
maintenance dose via intravenous route, with no
immediate repeat doses. Continue regimen until
birth or for 24 hours, whichever comes first.
C 10
• Regardless of plurality (number of babies in utero). B 11
• Regardless of the reason women (at less than
30 weeks gestation) are considered to be at
risk of preterm birth.
B 12
• Regardless of parity (number of previous
births for the woman).
B 13
• Regardless of anticipated mode of birth. B 14
• Regardless of whether or not antenatal
corticosteroids have been given.
B 15
^These grades are based on the NHMRC’s standards for grading
recommendations for developers of guidelines, and reflect the degree of trust
that can be placed in a particular recommendation based on the strength of
the evidence (with A indicating the highest degree of trust).
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Preterm birth and cerebral palsy: the burden of disease
Babies born very early are at high risk of dying in their
first few weeks of life, or if they survive, they may have
damage to their developing brain, manifesting as cere-
bral palsy, blindness, deafness or cognitive dysfunction
[1-3]. Over 600 children in Australia and over 150 in
New Zealand are diagnosed with cerebral palsy each year
[4]; with approximately 40% of all cases being related to
preterm birth [5]. The rate of cerebral palsy among neo-
natal survivors born at less than 28 weeks gestation is
up to 30 times higher compared with infants born at
term [6]. It is estimated that the cost to the Australian
community of cerebral palsy alone (including financial
cost and lost wellbeing) is almost AUD$4 billion per
annum [4]. Preventing cerebral palsy and identifying
causes have been stated as lead priorities for research by
consumers, clinicians and researchers [7].
Magnesium sulphate and prevention of cerebral palsy:
the evidence base
Nearly twenty years ago, a case–control study first des-
cribed the association between antenatal magnesium prior
to preterm birth and the prevention of cerebral palsy [8].
The updated Cochrane review ‘Magnesium sulphate for
women at risk of preterm birth for neuroprotection of the
fetus’ [9], including five randomised controlled trials,
showed for the first time that magnesium sulphate given
to women prior to preterm birth can reduce the risk of
death or cerebral palsy (risk ratio 0.85, 95% confidence
interval 0.74 to 0.98; 4446 infants), and of cerebral palsy
alone (risk ratio 0.68, 95% confidence interval 0.54 to 0.87;
6145 infants). The Cochrane review showed that 63
women need to be treated with antenatal magnesium
sulphate for neuroprotection for one baby to avoid cere-
bral palsy. The corresponding number needed to treat to
benefit for combined death or cerebral palsy was 42 [9].
This was a very important finding, as few interventions to
date have been found to prevent the devastating and life-
long consequences of cerebral palsy.
Clinical practice guidelines for the use of antenatal
magnesium sulphate for neuroprotection of the fetus,
infant and child
Researchers at the Australian Research Centre for Health of
Women and Babies (ARCH) within the Robinson Institute
at the University of Adelaide, led a rigorous guideline
development process, culminating in the 2010 National
Health and Medical Research Council (NHMRC) endorsed
Australian and New Zealand clinical practice guidelines
for magnesium sulphate for women at risk of early pre-
term (less than 30 weeks gestation), imminent birth
(planned or definitely expected within 24 hours) [10].
These clinical practice guidelines ‘Antenatal magnesiumsulphate prior to preterm birth for neuroprotection of the
fetus, infant and child’ [10] provide detailed guidance in
the form of nine evidence-based recommendations and six
good practice points on how and when to use antenatal
magnesium sulphate prior to very preterm birth for fetal
neuroprotection (Table 1).
Translating research recommendations into clinical
practice
Even with up-to-date and relevant guidelines, it was not
anticipated that health professionals caring for women at
risk of an early preterm birth would immediately begin
using antenatal magnesium sulphate for fetal neuroprotec-
tion without some form of active implementation strategy
(apart from passive dissemination). The slow uptake of
antenatal corticosteroids for anticipated preterm birth into
clinical practice clearly illustrated that “the transfer of
valid and relevant research findings into routine practice
is unpredictable and tends to be slow and haphazard”
[11]. Consequences of slow adoption into practice can be
dire. For example, if the change from the initial 20% to
75% uptake of antenatal corticosteroids had happened
more rapidly, over 400 additional babies’ lives would have
been saved each year in England and Wales [12].
For antenatal magnesium sulphate, an unparalleled op-
portunity was presented to close an evidence-practice
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in doing so, increase the likelihood of babies born very
preterm surviving free from cerebral palsy. We propose
to do this by initiating and implementing strategies
shown to be effective in increasing the uptake of appro-
priate care [13-20].
Implementation often follows identification of evidence-
practice gaps and/or variation in practice. Barriers to
the uptake of evidence can operate at many levels (the
innovation itself; individual professionals or consumers;
and social, organisational, economic and political con-
texts). There are also many categories of barriers – feasi-
bility, accessibility, knowledge, motivation, resources,
organisational culture, financial arrangements are just
some of these [21,22]. While it was considered likely that
multifaceted practice change interventions would be more
effective than single interventions, the optimal combina-
tions are not yet known for many clinical settings –
including obstetric clinical practice [13]. The interventions
selected for this project were thus chosen on the basis of
resulting in likely benefit (increased uptake of the recom-
mended treatment) and ability to integrate the interven-
tions into the setting of caring for women about to give
birth very early.
Summary
 High-quality research evidence has clearly shown
that antenatal magnesium sulphate prior to
imminent, early preterm birth significantly increases
the chances of children surviving free of cerebral
palsy;
 Antenatal magnesium has not previously been used
routinely for the indication of fetal, infant and child
neuroprotection;
 With this ‘translational flashpoint’, implementation
interventions are needed to promptly increase
uptake into routine care, thereby preventing
unnecessary deaths or children surviving with
cerebral palsy;
 This translation process is likely to be accelerated
with active implementation strategies compared
with passive dissemination, and by identifying and
addressing barriers to implementation;
 This project will offer active implementation
interventions (and assess the effectiveness of these
translational interventions), monitor rates of
appropriate uptake of antenatal magnesium sulphate
prior to early preterm birth, and monitor deaths of
infants prior to primary hospital discharge and
rates of cerebral palsy in early childhood. In the
longer-term, there may be the ability to assess the
impact on cerebral palsy in later childhood for this
cohort (subject to the availability of future funding).Aims
The overall aim of this project is to optimise the care of
women at risk of very early preterm birth and so improve
the chances of survival and long-term good health for
their preterm babies. The project will also provide data
from a cohort of mothers and their babies born early that
will allow monitoring of the use of a new therapy and im-
plementation strategies for the prevention of cerebral
palsy, assess the changes in mortality and morbidity, and
provide clinical indicators for care that can be used for
quality improvement within participating hospitals.
The specific aims of this project are to improve and
monitor uptake of the use of antenatal magnesium sul-
phate as a neuroprotective therapy immediately prior to
imminent (birth planned or definitely expected within
24 hours), early preterm birth (less than 30 weeks gesta-
tion) [10], to reduce the risk of very preterm babies dying
or having cerebral palsy.
Methods/Design
A prospective cohort study will be conducted. The pro-
ject will also have a qualitative component which will
assess barriers and enablers to changes in practice.
Entry criteria
Hospital sites eligible to receive active implementation
interventions
All 25 tertiary level maternity hospitals within Australia
and New Zealand with a neonatal intensive care unit will
be eligible to receive active implementation interventions
(Additional file 1). Clinical practice recommendations are
that women at risk of an early birth are transferred to an
institution with neonatal intensive care facilities. The ter-
tiary level facilities are therefore the most likely sites
where magnesium sulphate for neuroprotection will be
administered immediately prior to imminent preterm
birth, as per the bi-national clinical practice guideline re-
commendations [10].
All eligible hospitals will be invited to join the project
and to nominate a local clinical implementation leader to
be a member of the ‘WISH Study Group’ with the aim, at
their institution, of promoting the use of antenatal magne-
sium sulphate as a fetal neuroprotective therapy, prior to
imminent, early preterm birth; with the option of partici-
pating in the ‘WISH audit of uptake and health outcomes
data collection’, monitoring uptake, mortality and cerebral
palsy.
Women eligible at hospital sites participating in the ‘WISH
audit of uptake and health outcomes data collection’
Eligible women at hospitals participating in the ‘WISH
audit of uptake and health outcomes data collection’
(Additional file 1) will be those giving birth after 22 com-
pleted weeks of gestation and before 30 weeks gestation
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genital anomalies).
Implementation interventions
Active dissemination and strategies to implement the
Australian and New Zealand antenatal magnesium
sulphate clinical practice guidelines at all eligible hospital
sites
A package of active implementation strategies (chosen on
the basis of likely benefit) will include the guided intro-
duction and local adaptation of guideline recommenda-
tions, in-service education [14,17], academic detailing
[18], reminders [14] and audit and feedback [13,14,16].
The local clinicians will be encouraged to adapt the ante-
natal magnesium sulphate guidelines in line with their
local hospital protocols and produce algorithms to com-
municate work flow and decision points [13].
Each hospital will also be provided with a WISH Project
Guideline Action Pack (GAP). The GAP includes a ‘tool
kit’ of information developed by the WISH Study Group
to aid in implementation [14,20], including the NHMRC
endorsed guidelines, educational materials including a
PowerPoint for use in in-services, health professional and
consumer information (Additional files 2 and 3), posters
(Additional file 4) and reminder hospital record inserts
(Additional file 5).
Each hospital will be strongly encouraged to form a
local implementation group (or identify a local leader)
[13,19], with the actual composition to be determined at
the local level. The local implementation group will be
guided to use the GAP materials to suit local needs. For-
mal and informal in-service education sessions will be en-
couraged [17], as well as one-on-one discussions with
health professionals caring for women at risk of very pre-
term birth to address any individual questions and con-
cerns (academic detailing) [18].
We will use audit and feedback, as this has been identi-
fied as an effective strategy [13], particularly where base-
line adherence to recommended practice is low and where
intensive feedback can be given [16]. A regular newsletter
will be sent to all hospitals for distribution to relevant
local health professionals highlighting overall progress in
the project, and giving information on the latest rates of
uptake of magnesium sulphate for neuroprotection from
those sites participating in the ‘WISH audit of uptake and
health outcomes data collection’.
Project outcomes
Project outcomes for all eligible hospital sites
Outcomes relating to local implementation progress and
the WISH Project strategies will be evaluated in all eligible
hospital sites across Australia and New Zealand during
the early phase of the intervention, and again in the later
intervention phase: Local guideline information; including the
proportion of eligible hospital sites following a
guideline for antenatal magnesium sulphate;
 Evaluation of uptake; including the proportion of
eligible hospital sites evaluating uptake of antenatal
magnesium sulphate;
 The perceived usefulness of WISH Project active
implementation strategies and materials; including
the proportion of eligible hospital sites using the
WISH GAP materials; and the proportion of
hospital that perceive the WISH GAP materials as
useful.Primary health outcomes for hospital sites participating in
the ‘WISH audit of uptake and health outcomes data
collection’
 The proportion of women giving birth after 22
completed weeks gestation and before 30 weeks
gestation (excluding known lethal congenital
anomalies) receiving antenatal magnesium sulphate
(judged to be eligible for such treatment according to
the bi-national clinical practice guidelines [10]) during
three consecutive years;
 Deaths prior to primary hospital discharge of babies
born after 22 completed weeks gestation and before
30 weeks gestation during three consecutive years;
 Cerebral palsy rate at early childhood follow-up
(two years corrected age) in babies born alive after 22
completed weeks gestation and before 30 weeks gesta-
tion in the first year of three consecutive years. The
importance of follow-up of this cohort is recognised;
further support will be sought to ensure the timely and
ongoing collection of the highest quality follow-up data
including at preschool and early school age.Secondary health outcomes for hospital sites participating
in the ‘WISH audit of uptake and health outcomes data
collection’
 Serious adverse events related to administration of
magnesium sulphate therapy;
 Total dose of magnesium sulphate administered per
woman.Additional outcomes
For hospital sites wishing to undertake an in-depth as-
sessment of factors influencing uptake locally, barriers
and enablers to the use of antenatal magnesium sulphate
as perceived by health care professionals will be assessed
during the early phase of the intervention, and again in
the later intervention phase.
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For all eligible hospital sites
The 25 eligible hospital sites across Australia and New
Zealand will be surveyed using a web-based system during
the early phase of the intervention, and again in the later
intervention phase. The invitation to participate will be
directed to a local clinical implementation leader, and will
be voluntary, with consent implied by completion of the
survey.
The surveys will collect information relating to the fol-
lowing content areas: Demographic information (including
participating hospital; position in hospital of respondent);
Local guideline information (including whether a local
guideline for antenatal magnesium sulphate for fetal neu-
roprotection is being followed; the nature of the guideline;
the availability of the guideline; methods used to release
the guideline to health professionals; perceived barriers
and enablers to guideline implementation); WISH Project
strategies and materials (including whether a local imple-
mentation group/leader is in place; whether educational
sessions have been held; and the use and usefulness of the
GAP materials: PowerPoint presentation, health profes-
sional and consumer information brochures, posters and
reminder hospital record inserts); and Evaluation of uptake
(whether a process in place to evaluate uptake; methods
used; and approximations). Questions will largely provide
Yes, No and Unsure options, with the opportunity to add
comments. Views on WISH Project strategies and GAP
materials will be elicited by seeking the level of usefulness
using a five-point Likert scale (very useful; somewhat use-
ful; undecided; not really useful; not at all useful).
For hospital sites participating in the ‘WISH audit of uptake
and health outcomes data collection’
All eligible women who give birth after 22 completed
weeks gestation and before 30 weeks gestation (exclu-
ding known lethal congenital anomalies) at the partici-
pating hospitals will be given the project information
sheet and counselled by a member of the research team
about participating in the project. Women will then be
given the opportunity to discuss their participation with
their families. Informed, written consent will be obtained
by the research team if the woman agrees to participate
in the project.
For the woman and her baby, consent to enrol in the
project will provide consent to access information from
the maternal and neonatal clinical records. Mothers of
children who survive to primary hospital discharge will be
invited to complete the Ages and Stages Questionnaire at
12 and 24 months corrected age, providing information
about their child’s health and development [23].
Information will be collected from the maternal case
record on maternal demographic characteristics, mode
of birth, reason for preterm birth, use of antenatalcorticosteroids, tocolysis, eligibility for magnesium
sulphate, and whether magnesium sulphate was given. If
magnesium sulphate was given, the reason for magne-
sium sulphate, total dose administered, gestational age
given, whether loading, maintenance or repeat doses
were used, and timing prior to birth will be recorded to-
gether with any adverse effects. For the infant, stillbirth
and death of live-born infants prior to primary hospital
discharge will be collected.
Information on early child health will also be sought
from the child health record up to two years corrected
age, in liaison with the family, from any formal paediat-
ric assessment of motor function and psychological
assessment.
For hospital sites undertaking an in-depth assessment of
barriers and enablers
Face-to-face interviews will be conducted with randomly
selected, consenting health professionals (obstetric and
neonatal) during the early phase of the intervention, and
again in the later intervention phase. Interviewees will be
asked a range of semi-structured questions regarding their
awareness and use of the magnesium sulphate clinical
practice guidelines, and perceived factors influencing the
uptake of this therapy (including barriers and enablers to
use, and suggestions to improve uptake locally).
Data analyses
For all eligible hospital sites
WISH Project outcomes for the early intervention phase
of the project (Year 1) relating to local implementation
of a guideline for antenatal magnesium sulphate and
WISH Project strategies and materials will be compared
with the later intervention phase (Years 2 and 3).
For hospital sites participating in the ‘WISH audit of uptake
and health outcomes data collection’
Project outcomes for the early phase of the project (Year 1)
will be compared with the later intervention phase (Years 2
and 3). The proportion of eligible women prescribed mag-
nesium sulphate will be analysed with Chi2 tests (p values
of 0.05 regarded as statistically significant) for the earlier
period, compared with the later period. Similarly, the rates
of death prior to primary hospital discharge for the earlier
project period will be compared with the later period. In-
dividual adverse events will be presented as average rates
per woman receiving magnesium sulphate. Uptake of
magnesium sulphate and rates of death prior to primary
hospital discharge after birth will be graphed over time to
assess trends; the proportion of infants born during Year 1
with cerebral palsy (identified by age two) will be com-
pared with proportions identified in the literature; with
the opportunity, subject to further funding, to compare
with proportions born during Years 2 and 3.
Crowther et al. BMC Pregnancy and Childbirth 2013, 13:239 Page 6 of 7
http://www.biomedcentral.com/1471-2393/13/239For hospital sites undertaking an assessment of barriers
and enablers
Qualitative data from the semi-structured interviews
with health professionals involved in the care of women
at risk of an early birth will be transcribed and grouped
into themes, using one or more of the theoretical frame-
works of behaviour change and motivation, that have
been used for analysis of barriers and enablers in the
translation from ‘knowing to doing’ [24,25]. Themes
from the early intervention phase of the project (Year 1)
will be compared with the later intervention phase
(Years 2 and 3).Ethical considerations
Ethics approval for the WISH Project has been granted
by the Children’s Youth and Women’s Health Service
(CYWHS) Human Research Ethics Committee at the
Women’s and Children’s Hospital, Adelaide, Australia
(REC2304/8/13). Ethics approval for participation in the
‘WISH audit of uptake and health outcomes data collection’
has been granted by the local institutional review boards
for each participating hospital site (see Additional file 1).
Hospital sites wishing to undertake an assessment of bar-
riers and enablers will require ethics approval from their
local institutional review boards.Discussion
There is strong evidence that antenatal magnesium sul-
phate given to women prior to early preterm (at less than
30 weeks gestation), imminent birth (when birth is
planned or definitely expected within 24 hours) signifi-
cantly increases the chances of their babies surviving free
of cerebral palsy [9,10]. It is anticipated that the active im-
plementation strategies used in this project, believed to be
effective in increasing the uptake of appropriate care, will
lead to a significant increase in the appropriate use of
antenatal magnesium sulphate for women prior to early
preterm birth. It is estimated that the successful adoption
into clinical practice of this valid and relevant research
could lead to over 90 fewer very preterm babies dying or
suffering the long-term consequences of cerebral palsy in
Australia and New Zealand each year [26,27], and should
accordingly reduce the burden of this condition on
Australian and New Zealand individuals, families and
communities.Additional files
Additional file 1: All eligible hospital sites and those participating
in the ‘WISH audit of uptake and health outcomes data collection’.
List of all hospital sites eligible to receive WISH active implementation
strategies, and list of hospital sites with ethics approval for participation
in the ‘WISH audit of uptake and health outcomes data collection’.Additional file 2: 3-Fold Information Sheet: Summary of clinical
recommendations and good practice points for health professionals.
This brochure can be distributed to all health professionals involved in
the care of women at risk of very preterm birth to help raise awareness
and use of the clinical practice guidelines.
Additional file 3: 3-Fold Patient Information Sheet: Antenatal
magnesium sulphate therapy for improving the health of preterm
babies: information for women. This brochure can be given to women
at risk of a very preterm birth.
Additional file 4: Magnesium sulphate implementation poster.
These posters can be put up in perinatal care areas to assist with
implementation of the clinical practice guidelines.
Additional file 5: Case note reminder insert for magnesium
sulphate. These case note inserts can be placed in the medical records
of women at risk of very preterm birth to remind clinicians to consider
their patient’s eligibility for antenatal magnesium sulphate.
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